Compare RCMT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | TNYA |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.3M | 168.2M |
| IPO Year | 1997 | 2021 |
| Metric | RCMT | TNYA |
|---|---|---|
| Price | $29.40 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $36.00 | $5.33 |
| AVG Volume (30 Days) | 31.4K | ★ 2.0M |
| Earning Date | 04-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 54.96 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $54.87 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $0.53 |
| 52 Week High | $32.50 | $2.35 |
| Indicator | RCMT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 40.77 |
| Support Level | $27.02 | $0.65 |
| Resistance Level | $29.38 | $0.80 |
| Average True Range (ATR) | 0.78 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 60.12 | 0.00 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.